Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease.
about
Asymmetric dimethyarginine as marker and mediator in ischemic strokeDimethylarginine dimethylaminohydrolase (DDAH) overexpression attenuates agricultural organic dust extract-induced inflammationRegulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma.Dimethylarginine metabolism during acute and chronic rejection of rat renal allograftsDimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertensionAn update on uremic toxins.Role of Endothelial Cells in Myocardial Ischemia-Reperfusion Injury.Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.In vivo bioluminescence for tracking cell fate and function.Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance.Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitusADMA: its role in vascular disease.Generation of NO by bystander human CD8 T cells augments allogeneic responses by inhibiting cytokine deprivation-induced cell deathHow to control NO production in cells: N(omega),N(omega)-dimethyl-L-arginine dimethylaminohydrolase as a novel drug target.Cellular magnetic resonance imaging: current status and future prospects.Cellular MRI and its role in stem cell therapy.Effect of asymmetric dimethylarginine (ADMA) on heart failure development.Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide productionCharacterization of a fluorescent probe for imaging nitric oxide.Perspective in chronic kidney disease: targeting hypoxia-inducible factor (HIF) as potential therapeutic approach.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.DDAH says NO to ADMARole of asymmetric dimethylarginine in cardiovascular disease and diabetes.Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption.an Obituary for GFR as the main marker for kidney function?Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.
P2860
Q26864318-7BCF2B5C-65BD-4080-9C6A-E4212B29D7D8Q28394020-E822CC69-5369-4E40-A931-0D087F6F6A48Q33589158-9FBA5D1B-AE67-48BA-9BD5-7723AEBA1E6CQ33816492-531E5F8B-5357-4B3E-B863-5DC05187712AQ34426054-3B122077-C41C-4525-AF94-956009A56DF8Q34426973-065766FD-4F5B-474E-BEB5-6A94A36AF677Q34460993-1FC91E63-6ACB-433A-8679-4029796B505AQ34641464-FD2EBFC0-A776-4C0B-A507-DE10BB26D4A5Q34794828-4B8F795A-3456-4C1E-84EA-644AABB1C140Q35090446-CEA161F8-87E6-4E2C-A384-75EEA282D6E9Q35314819-07836D87-7530-4B6E-B0A7-3F552996E9F4Q35540671-25A47AD4-BDFE-4E0B-A037-D74E218E784EQ35622245-ABFB76D6-D4E7-43B6-B516-9FFC8C427C35Q36380994-C936DA56-09D5-40B8-8B5D-0DD1E2B25160Q36420656-7E58766C-4D6F-4791-8AB2-BC45ADFF7606Q36471209-F16CC328-B06E-4BCD-9143-9823BE7B8015Q36546298-DC018E62-A88E-4A5E-82ED-390275EF6BEAQ37096959-B040DFD2-1D83-432D-93F1-A8B4DD197733Q37245523-F7F7A2E4-1F79-4EAA-841A-9174CB68046CQ37370528-DE8829DE-5D5F-428A-8EC1-9E46ED5FB108Q37467533-C76952E6-CD59-459B-8314-958EE55872DFQ37580114-6969107A-3D11-43BF-8B22-03593A4EE092Q37591188-888240C0-D959-4FDC-9BAC-E1E071EC7319Q37977513-761249F3-B4EE-4283-8FF3-B12F3CD5B328Q38203518-4FD0F1A4-8A03-4A43-AEB0-5597193B7481Q42791219-E3B87A2A-E5F6-45C1-B31D-FEF95B15D7A6Q43061621-032CB80F-78A6-4766-A68B-CF82A579EAFAQ43074669-9675F3F1-33CA-4CEA-9B4E-227E400FBB63Q46107442-961A4FE0-94C0-4BF0-8F5A-BB08B893029DQ47216784-F17005DB-257E-4E6E-8718-A7C1E5EADB55
P2860
Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@ast
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@en
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@nl
type
label
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@ast
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@en
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@nl
prefLabel
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@ast
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@en
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@nl
P2093
P1433
P1476
Dimethylarginine dimethylamino ...... graft coronary artery disease.
@en
P2093
Feny Gunawan
Johannes Jacobi
John P Cooke
Karsten Sydow
Masashi Tanaka
Phil S Tsao
Robert C Robbins
P304
P356
10.1161/CIRCULATIONAHA.105.537670
P407
P577
2005-09-06T00:00:00Z